Evidence map›Paper›PMID 30211746›Full record

ReviewCornea2018

Innovative Development of Contact Lenses.

Hidenaga Kobashi, Joseph B Ciolino

Open access · greenAbstract readReview
In one paragraph

Review in Cornea, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Hidenaga KobashiDepartment of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA.
Joseph B CiolinoDepartment of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston, MA.
Harvard University · USSmith-Kettlewell Eye Research Institute · US

Funding

Antibiotic eluting contact lenses for the treatment of bacterial keratitisR01EY026640 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI CIOLINO, JOSEPH B. · 2017 to 2020
$2.0M
NEI NIH HHS R01 EY026640
6 · The paper itself

Abstract

Contact lenses have been a common means of vision correction for more than half a century. Recent developments have raised the possibility that the next few decades will see a considerable broadening of the range of applications for contact lenses, with associated expansions in the number and type of individuals who consider them a valuable option. The novel applications of contact lenses include treatment platforms for myopic progression, biosensors, and ocular drug delivery. Orthokeratology has shown the most consistent treatment for myopia control with the least side effects. Recent work has resulted in commercialization of a device to monitor intraocular pressure for up to 24 hours, and extensive efforts are underway to develop a contact lens sensor capable of continuous glucose tear film monitoring for the management of diabetes. Other studies on drug-eluting contact lenses have focused on increasing the release duration through molecular imprinting, use of vitamin E, and increased drug binding to polymers by sandwiching a poly (lactic-co-glycolic acid) layer in the lens. This review demonstrates the potential for contact lenses to provide novel opportunities for refractive management, diagnosis, and management of diseases.

Indexed as

Contact LensesBiosensing TechniquesDiabetes MellitusDrug Delivery SystemsGlucoseHumansMonitoring, PhysiologicOcular HypertensionOrthokeratologic ProceduresRefractive ErrorsTearsGlucose

Identifiers

PMID30211746
PMCPMC8554537
OpenAlexW2890532676

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.